https://www.selleckchem.com/pr....oducts/Irinotecan-cp
3 months, respectively, P less then 0.001). Patients who did not experience SAEs showed longer OS than those who did (median OS 18.8 and 7.5 months, respectively, P less then 0.05). Patients with distant metastasis had shorter median OS than those with loco-regional disease, but without statistically significant difference (3.6 and 16.1 months, respectively, P = 0.19). CONCLUSIONS ERB showed a promising response rate and is a potential candidate for second-line treatment in CAS patient after taxane. However, the occurrence of